Legally Bland
Well-Known Member
- Joined
- Nov 17, 2015
- Messages
- 8,789
- Reaction score
- 43,349
The Oxford/AstraZeneca half dose trials were a mistake:
“The reason we had the half dose is serendipity,” said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca.
When university researchers were distributing the vaccine at the end of April, around the start of Oxford and AstraZeneca’s partnership, they noticed expected side effects such as fatigue, headaches or arm aches were milder than expected.
“So we went back and checked … and we found out that they had underpredicted the dose of the vaccine by half,” said Pangalos.
Instead of restarting the trial, he said researchers decided to continue with the half dose and administer the full dose booster shot at the scheduled time.
Oxford Covid vaccine hit 90% success rate thanks to dosing error
“The reason we had the half dose is serendipity,” said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca.
When university researchers were distributing the vaccine at the end of April, around the start of Oxford and AstraZeneca’s partnership, they noticed expected side effects such as fatigue, headaches or arm aches were milder than expected.
“So we went back and checked … and we found out that they had underpredicted the dose of the vaccine by half,” said Pangalos.
Instead of restarting the trial, he said researchers decided to continue with the half dose and administer the full dose booster shot at the scheduled time.
Oxford Covid vaccine hit 90% success rate thanks to dosing error